Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote
by Zacks Equity Research
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
Why Is Horizon Therapeutics (HZNP) Up 7.5% Since Last Earnings Report?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.
Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 25.49% and 0.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HZNP or BMRN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HZNP vs. BMRN: Which Stock Is the Better Value Option?
Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus
by Zacks Equity Research
Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Why Is Horizon Therapeutics (HZNP) Down 3.3% Since Last Earnings Report?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates
by Zacks Equity Research
Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.
Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 36.84% and 7.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Horizon Therapeutics (HZNP) Q2 Earnings Expected to Decline
by Zacks Equity Research
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon's NDA for Procysbi New Dosage Form Accepted by FDA
by Zacks Equity Research
The FDA accepts Horizon Therapeutics' (HZNP) NDA for Procysbi (Cysteamine Bitartrate) delayed-release oral granules in packets.
Horizon Therapeutics Files BLA to FDA for Eye Disease Drug
by Zacks Equity Research
Horizon Therapeutics (HZNP) files a BLA for teprotumumab to the FDA for the treatment of active thyroid eye disease.
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates
by Zacks Equity Research
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
Horizon Pharma (HZNP) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Horizon Pharma (HZNP) delivered earnings and revenue surprises of 200.00% and 18.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Axsome (AXSM) This Earnings Season?
by Zacks Equity Research
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
What's in the Cards for AcelRx (ACRX) This Earnings Season?
by Zacks Equity Research
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
Guardant Health (GH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.
Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.
What's in Cards for Cumberland (CPIX) This Earnings Season?
by Zacks Equity Research
Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.
Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.